Skip to main content

Table 2 Cox regression analysis of death and reoperation

From: Long-term survival after Carpentier-Edwards Perimount aortic valve replacement in Western Denmark: a multi-centre observational study

 

Death

Reoperation

Hazard Ratio (95% CI)

P-value

Hazard Ratio (95% CI)

P-value

Male gender

1.07 (0.92–1.24)

0.360

1.56 (0.91–2.66)

0.107

Age groupa

 65–70

1.0

 

1.0

 

  < 50

1.35 (0.55–3.33)

0.516

5.61 (1.59–19.8)

0.007*

 50–65

1.05 (0.74–1.51)

0.77

2.44 (1.17–5.08)

0.017*

 70–80

1.81 (1.43–2.28)

< 0.001*

0.71 (0.37–1.38)

0.312

  ≥ 80

3.19 (2.46–4.12)

< 0.001*

0.60 (0.21–1.70)

0.337

Reoperationb

1.06 (0.74–1.52)

0.747

  

Valve size

 25

1.0

 

1.0

 

 19–23

1.22 (1.03–1.45)

0.025*

0.73 (0.42–1.26)

0.252

 27–29

0.94 (0.71–1.25)

0.658

1.03 (0.45–2.34)

0.948

Diabetes Mellitus

1.22 (0.99–1.51)

0.067*

1.38 (0.68–2.81)

0.369

Smoker

1.59 (1.29–1.97)

< 0.001*

1.61 (0.74–3.52)

0.234

Previous smoker

1.08 (0.91–1.28)

0.383

1.39 (0.77–2.51)

0.269

VP-PM

1.18 (0.95–1.48)

0.144

2.19 (1.21–3.98)

0.010*

EuroSCORE II < 4%

0.61 (0.43–0.87)

0.006*

0.12 (0.06–0.22)

< 0.001*

Hypertension treatment

1.01 (0.87–1.17)

0.889

0.98 (0.59–1.64)

0.945

Lipid-lowering treatmentc

0.68 (0.58–0.80)

< 0.001*

1.09 (0.61–1.96)

0.759

  1. VP-PM Valve prosthesis-patient mismatch. *P < 0.05
  2. aAge groups for reoperation are sorted by the age of the primary CE-P procedure
  3. bReoperation after primary AVR with another CE-P or TAVR
  4. cCox regression of the first 10 years